2 ] (4) towards amino acids, nucleotides, and a single-stranded DNA dodecamer were studied using NMR and mass spectrometry. In aqueous solutions at 37 C, the monothiolato complexes 1 and 2 undergo rapid hydrolysis, irrespective are inert toward nucleotides and DNA, suggesting that DNA is not a target of cytotoxic thiolato-bridged arene ruthenium complexes. In contrast to the trithiolato complexes, monothiolato and dithiolato complexes hydrolyse and react with L-cysteine. These results may have important implications for the mode of action of thiolato-bridged dinuclear arene ruthenium drug candidates, and suggest that their modes of action are different to those of other arene ruthenium complexes.
Introduction
Ever since the serendipitous discovery of the anticancer properties of cisplatin in 1965 1 and its clinical use in 1978, 2 the research on platinum cytostatics has ourished. A plethora of analogous square-planar platinum(II) and octahedral platinum(IV) complexes was synthesised and studied in order to nd more selective and less toxic alternatives. 3 Despite immense efforts, only two additional platinum complexes were approved for global use in the clinic so far: the second-generation drug carboplatin was approved by the FDA in 1989 and the thirdgeneration oxaliplatin in 2002. 4 Unfortunately, none of the three agents possess very high selectivity towards cancerous cells; their therapeutic application therefore causes severe side effects such as nephrotoxicity, 5-7 neurotoxicity 8,9 and nausea.
8,10
In order to overcome these side-effects, part of the research on metallodrugs has shied from platinum to ruthenium-based anticancer agents. Ruthenium compounds have in general lower systemic toxicity than platinum drugs, they can access a wide range of oxidation states under physiological conditions and have a very similar ligand exchange rate as platinum complexes. 11 The eld of anticancer ruthenium compounds was pioneered by Alessio, Sava and Keppler, who developed ruthenium(III) imidazole and indazole complexes, the imidazolium or indazolium salts of which (termed NAMI-A and KP1019, respectively) have already entered clinical trials. [12] [13] [14] [15] The sodium analogue of KP1019, termed NKP-1339, is now on the edge of clinical application.
In 1992, Tocher and co-workers have observed a cytotoxicity enhancement by coordinating the anticancer agent metronidazole [1-b-(hydroxyethyl)-2-methyl-5-nitro-imidazole] to a benzene ruthenium dichlorido fragment. 17 Subsequently, it became obvious that water-soluble arene ruthenium complexes are in general cytotoxic, since they seem to have the right balance between lipophilicity and hydrophilicity, essential for cellular uptake. 18 The rst prototype arene ruthenium(II) + as hexauorophosphate or chloride salt from Sadler's laboratory. 20 Importantly, although RAPTA-C only exhibits a low activity in vitro, it is very active in vivo, where it inhibits lung metastases in CBA mice. 21 Therefore, RAPTA-C can be considered as an antimetastatic agent like NAMI-A. 21, 22 RAED compounds are highly cytotoxic to a range of cancer cell lines, 23 including cisplatin-resistant cell lines. An in vivo study established that RM175, [(h 6 -C 6 H 5 Ph)Ru(N,N-en)Cl]PF 6 , is active against MCa mammary carcinoma and causes metastasis reduction. 24 In addition to these two prototype compounds, a plethora of organometallic ruthenium(II) compounds have been prepared and their cytotoxicity to cancer cells examined.
25-33
In recent years, we have synthesised several series of dinuclear arene ruthenium thiolato-bridged complexes of the general formula [(h 6 -arene) 2 intermediates in the formation of the cationic trithiolato complexes, thus opening new avenues for the ne-tuning the properties of dinuclear thiolato-bridged arene ruthenium complexes (Scheme 1).
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Interestingly, the mono-and dithiolato analogues are systematically at least one order of magnitude less cytotoxic than their trithiolato counterparts. 36, 38, 39 The stability and reactivity studies of some trithiolato complexes with various amino acids, peptides, nucleotides and DNA revealed that the complexes are very stable in physiological conditions as well as under acidic and basic conditions and that they are particularly inert towards substitution. Only the sulphur-containing biomolecules cysteine (Cys) and the tripeptide glutathione (GSH) interact with the complexes. Unexpectedly, no adducts were identied, but Cys and GSH undergo a catalytic oxidation in the presence of the trithiolato complexes, forming cystine and GSSG. 35 Such a mode of action has already been proposed for arene ruthenium azopyridine iodo complexes, which are surprisingly cytotoxic despite their inertness to ligand substitution. 44 Although a decrease in the glutathione levels with increasing concentration of diruthenium-1 was observed in vitro and in vivo, 40 no direct correlation between their cytotoxicity and catalytic activity for the oxidation of glutathione was found. 36, 38, 39 We therefore assume that other mechanisms are mainly responsible for the high in vitro cytotoxicity of the trithiolato complexes.
In an effort to rationalise the relationship between reactivity and the in vitro cytotoxicity of thiolato-bridged arene ruthenium complexes, we set out to investigate the hydrolysis of two monothiolato complexes 1 and 2 and two dithiolato complexes Scheme 1 Stepwise synthesis of thiolato-bridged arene ruthenium complexes.
3 and 4 ( Fig. 1) as well as their interactions with selected amino acids, nucleotides and a single-stranded DNA dodecamer. The coordinated thiolato bridge can come off as thiol to be replaced by a thiolato bridge derived from another thiol, which leads to a mixture of thiolato complexes. These equilibria are governed mostly by the reactivity of the thiols and to a lesser extent by the choice of the solvent and reaction conditions. shows that 3 is the major species present in the mixture. In the case of 4, additional resonances also appeared immediately aer sample preparation, indicating rapid hydrolysis, and the equilibrium is reached rapidly aer about 2 h (Fig. 4) 1 H NMR spectra shows that 4 is the major species present in the mixture (Fig. S13 †) .
Results and discussion

Stability of the dithiolato complexes 3 and 4 in aqueous solution
Reactivity of 1-4 with nucleotides and DNA
In general, arene ruthenium compounds have been shown to bind to DNA model compounds 45, 46 via loss of the chlorido ligands, and loss of the arene was also observed. More importantly, by using a 14-mer oligonucleotide, it has not been possible to identify preferential binding sites, due to the multiple interactions that are available.
Upon addition of 3 eq. of dAMP and dGMP, no changes in the NMR spectra are observed for complexes 2 and 3. As an example, the 2D-1 H DOSY NMR spectrum of the mixture 3 : dGMP (ratio 1 : 3) recorded aer 24 h is shown in Fig. S14 . † In the spectrum two species can be identied: one with the lowest diffusion coefficient being the hydrolysed derivative of 3, and the second species being free dGMP. Furthermore, inspection of the 1D In analogy with platinum complexes and some other ruthenium compounds, 20, 42, 47, 48 we assumed that complexes 1-4 could bind to the nucleophilic nitrogen of the nucleotides once they underwent hydrolysis. However, ESI mass spectroscopy spectra recorded in the negative and positive mode (Fig. S15 †) revealed that no adducts are formed between the mono-and dithiolato complexes and the single-stranded DNA 20-mer. Interestingly, we have previously shown that trithiolato complexes are also inert towards nucleotides and DNA. 35, 36 As such, unlike other arene ruthenium complexes, these results suggest that DNA is not a target of thiolato-bridged arene ruthenium complexes and that they exert their cytotoxicity through other mechanisms.
Reactivity of 1-4 with aspartic acid, alanine and histidine
Most of the metallodrugs currently used in antitumoural therapy, such as carboplatin and cisplatin, are administered intravenously and can therefore encounter various reactive biomolecules in the bloodstream. 20, 47 Interactions with peptides and serum proteins can have a pronounced inuence on the drug distribution, bioavailability and target or off-target effects. To investigate some of these possible interactions, the neutral amino acid Ala, the acidic amino acid Asp and the basic amino acid His were used. His was also chosen to investigate a possible binding between the imidazole ring and the ruthenium atom, since we and others already showed that imidazole rings strongly and rapidly interact with the ruthenium atom 49-54 and especially with arene ruthenium complexes.
55-58
Alanine usually does not react with ruthenium complexes, although a hexacationic arene ruthenium assembly possessing an oxalato linker slowly degrades in the presence of excess of Ala to give mononuclear ruthenium-alanine adducts. 53 Asp with a coordinating carboxyl side chains is known to form tridentate chelate complexes with ruthenium and other metal centres. 54, 55, 59 Upon addition of 3 eq. of Ala and Asp, no changes in the NMR spectra are observed for the four complexes 1-4 (Fig. 5 , S16 and S17 †). As an example, the 2D-1 H DOSY NMR spectrum of the mixture 1 : Ala (ratio 1 : 3) recorded aer 24 h is shown in Fig. 5 . In the spectrum four species can be clearly distinguished: two, with the lowest diffusion coefficient, being complex 1 and the hydrolysed derivative thereof, the third species being free Ala, and the fourth one acetone. Furthermore, inspection of the 1D 1 H and 2D-1 H DOSY NMR spectra shows a single aH resonance and a single bCH 3 resonance for Ala, suggestive of the absence of a coordination of Ala to the Ru atom. Upon addition of 3 eq. of His, surprisingly, both NMR and ESI mass spectrometry data strongly suggest that the mono-and dithiolato complexes 1-4 do not react with His ( Fig. 6 and S18 †) . As an example, the 2D-1 H DOSY spectrum of the mixture 3 : His (ratio 1 : 3) recorded aer 24 h is shown in Fig. 6 . In the spectrum two species can be clearly distinguished: one with the lowest diffusion coefficient being the hydrolysed derivative of complex 3, the second one being free His. Furthermore, inspection of the 1D 
Reactivity of 1-4 with cysteine and methionine
Reactions with the sulphur-containing amino acids Cys and Met appear to play key roles in the biological chemistry of platinum(II), platinum(IV) and ruthenium(III) anticancer agents, and were shown to form tridentate chelates with arene ruthenium complexes. 60 The nucleophilicity of methionine is less than that of cysteine, but still it is known to react with electrophilic sites.
61,62
Upon addition of 4 eq. of Met, NMR data strongly suggest that no reaction takes place between the mono-and dithiolato complexes 1-4 and Met. As an example, 1D H DOSY NMR spectra shows a single aH resonance and especially a single dCH 3 resonance for Met at d 2.15 ppm, suggesting that there is no coordination of the methionine sulphur atom to the Ru atom, because otherwise a characteristic high eld shi for the dCH 3 group would be expected as observed in such complexes. 63 However, upon addition of 4 eq. of Cys to the complexes 1-4, the spectra reveal that Cys reacts rapidly with the four complexes. In all cases, additional resonances appear immediately aer sample preparation, indicating a rapid reaction, and equilibrium is reached rapidly aer 2 h. As an example, the 2D-1 H DOSY NMR spectrum of the mixture 1 : Cys (ratio 1 : 3) recorded aer 24 h is shown in Fig. 8 . Three species can be clearly identied: the rst one with the lowest diffusion coefficient is attributed to an "adduct" containing cysteine and the dithiolato complex, the second species to free Cys, and the third one to acetone. A more in-depth analysis of the 1 H-and the 2D-1 H DOSY NMR spectra shows two distinct aH resonances (highlighted with a circle) at d 3.7 and 3.8 ppm, respectively, suggesting the presence of two types of cysteine, which is cross-conrmed by their different diffusion coefficient. The aH resonance at d 3.8 ppm has clearly the same diffusion coefficient than the p-cymene proton resonances, although it appears slightly out of alignment because of the close proximity of the intense water resonance at 4.64 ppm. The ESI-MS spectrum shown in Fig. 9 Similar results were obtained with complexes 2-4, the formation of the corresponding cysteinato-containing trithiolato complexes as the only species present in the mixtures aer 24 h is conrmed by both NMR and ESI-MS data (Fig. S20-S24 The in situ formation of cysteinato-containing trithiolato complexes is somewhat surprising, since our previous attempts to synthesise such complexes by standard methods were unsuccessful; only degradation of the arene ruthenium unit was observed. On the other hand, such complexes are conceivable in the light of the equilibria between the thiolato complexes and the thiol. 42, 43 For trithiolato complexes, the equilibria between the thiolato complexes and the thiol do not yield cysteinatocontaining trithiolato complexes but catalyse the oxidation of Cys to give cystine. (5) 41 was dissolved in a small amount of methanol and an aqueous solution of cysteine was added dropwise in large excess. The resulting mixture was stirred at ambient temperature for two days, and a gradual colour change from orange to yellow was observed. The resulting product was unstable at elevated temperature; it also degraded rapidly in purely organic solutions. The product was therefore puried by size exclusion chromatography on Sephadex® LH20 with a MeOH/H 2 O (9 : 1) mixture, evaporated at room temperature and dried in vacuo. Spectroscopic methods and elemental analysis proved the compound to be the tetrauoroborate salt of the cysteinato-containing trithiolato complex [(h Because of its low stability, it was not possible to obtain crystals suitable for X-rays analysis. Synthesis of the other cysteinato-containing trithiolato complexes starting from the dithiolato precursors 3 and 4 was also attempted, but the resulting complexes degraded rapidly and could not be isolated in analytically pure form. The synthesis of the cysteinatocontaining trithiolato complexes starting from the monothiolato precursors 1 and 2 was not attempted.
To the best of our knowledge, together with the two diruthenium complexes obtained fortuitously by Sadler et al., 61 complex 6 is only the second example of a dinuclear arene ruthenium complex containing a cysteinato bridge. Since intracellular biological environment contain millimolar amounts of the tripeptide glutathione (g-Glu-Cys-Gly), such complexes could be of considerable signicance inside cells. This is currently being further investigated.
Conclusions
As reported for many other arene ruthenium complexes, our results show that the presence of chlorido ligands makes monoand dithiolato complexes 1-4 less stable than their trithiolato counterparts, which do not have Ru-Cl bonds. The complexes 1-4 hydrolyse readily, though slowly in comparison with other arene ruthenium complexes like RAPTA-C and the RAED family of complexes. Our results also suggest that complexes 1-4 remain relatively inert towards model biomolecules and DNA, as adducts were only observed upon addition of Cys. Interestingly, unusual cationic dinuclear trithiolato complexes from which the chlorido ligands had been removed, such as [(h 6 -p- It can be assumed that the propensity of mono-and dithiolato complexes to hydrolyse and to react with sulphurcontaining molecules explains why they are at least an order of magnitude less cytotoxic than trithiolato complexes. As already demonstrated for mononuclear Ru(II)-arene complexes with O,O-bound alkoxycarbonylmethyl-3-hydroxy-2(1H)-pyridones, 65 our results suggest that there is a negative reactivity-in vitro cytotoxicity relationship for dinuclear thiolato-bridged arene ruthenium complexes: the more reactive mono-and dithiolato complexes are signicantly less cytotoxic compared to their trithiolato counterparts. The high stability of dinuclear arene ruthenium trithiolato complexes allows them to accumulate inside the cells of a tumour, 40 where they can reach their molecular target and deploy their anticancer activity. The monothiolato and dithiolato complexes, on the other hand, can potentially bind to proteins and other molecules containing sulydryl groups, which may impede their accumulation in cancer cells in sufficient concentration. However, the prominent examples of the arene ruthenium RAPTA complexes, which are reactive and only exhibit a low activity in vitro, but are very active in vivo, prompt us to further evaluate mono-and dithiolato complexes in in vivo and preclinical models.
Experimental section
4.1. Materials and methods 4.1.1. Chemicals. Analytical grade chemicals obtained from commercial suppliers were used as received. L-alanine, Laspartic acid, L-cysteine and L-histidine were purchased from Acros. GSH, Sephadex® LH20 and NaOD and DCl solutions were obtained from Sigma-Aldrich. The single-stranded DNA dodecamer (CGCGATCGCG) 2 was purchased from Microsynth. Complexes 1-4 and 5 were prepared according to previously published methods. NMR data were acquired with a standard longitudinal encodedecode pulsed-eld-gradient stimulated echo sequence containing bipolar gradients. 68 Experimental parameters were D ¼ 100 ms (diffusion delay), s ¼ 1 ms (gradient recovery delay) and T ¼ 5 ms (eddy current recovery delay). For each data set, 4 k complex points were collected, and the gradient dimension was sampled by means of 32 experiments in which the gradient strength was linearly increased from 1.0 to 50.8 G cm À1 . The gradient duration d/2 was adjusted to observe a near-complete signal loss at 50.8 G cm À1 . A 2 s recycle delay was used between scans for the data shown. 32 transients were recorded per experiments. For each data set, the spectral axis was processed with an exponential function (3-5 Hz line broadening), and a Fourier transform was applied to obtain 8 k real points. The DOSY reconstruction was realised with 8 k complex points in the detection dimension and with 128 points in the diffusion dimension. All NMR data were processed using TopSpin (Version 3.2, Bruker, Switzerland) and Dynamics Center (Version 2.3.1, Bruker, Switzerland). 4.1.3. Electrospray ionisation mass spectrometry. Massspectrometric (MS) analyses were performed with an LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientic, Bremen, Germany) equipped with a nanoelectrospray ion source. The samples were analysed in the positive or negative ion mode with a voltage of +700 V applied to the glass emitter (New Objective, Woburn, MA, USA). The tube lens was at +150 V and the transfer capillary was held at 200 C. Spectra were acquired in Fourier transform mass spectrometry mode over an m/z range from 100 to 2000 with a resolution of 100 000 at m/z 400. Calibration of the instrument was performed with ProteoMass LTQ/ FT-Hybrid electrospray ionisation (ESI) positive mode calibration mix (Supelco Analytical, Bellefonte, PA, USA). The Xcalibur soware package (Version 2.0.7, Thermo Fisher Scientic) was used for instrument control and data processing. 
Stability of 1-4 in aqueous solution
The stability of complexes 1-4 in aqueous solutions was studied by dissolving 1 mg of the complexes in the mixture of an appropriate deuterated solvent and water (D 2 O/acetone-d 6 
